PADN-HF-PH Trial Results Published in NEJM
Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Sep 03, 2026
The publication of positive trial results in a top medical journal is likely to boost Pulnovo Medical's credibility and accelerate adoption of its PADN system, potentially increasing its market share in the pulmonary hypertension treatment space. Competitors in the heart failure and pulmonary hypertension device market may face increased pressure as PADN gains clinical validation.
Pulnovo Medical announced that results from the PADN-HF-PH trial were presented at the European Society of Endocrinology (ESC) Congress 2026 and simultaneously published in The New England Journal of Medicine (NEJM). The multicenter, randomized, controlled trial involved 264 patients with pulmonary hypertension associated with left heart disease (PH-LHD). The trial evaluated the addition of Pulmonary Artery Denervation (PADN) to Guideline-Directed Medical Therapy (GDMT). Results showed a 51% reduction in the risk of clinical worsening, a 35.5% decrease in recurrent clinical events, and improvements in functional capacity and biomarkers. The therapy has regulatory approvals in 12 countries and has been referenced in seven clinical guidelines. The publication marks a significant milestone for cardiovascular interventions and provides evidence for a new treatment paradigm for PH-LHD.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard